Hepatitis/MASH

Pennsylvania health department recommends that patients be screened for HIV, and hepatitis B and C viruses.

Jury declares Merck’s acquired HCV drug patent valid.

Assistance program will provide financial assistance for FDA-approved HCV drugs.

Sofosbuvir/ribavirin treatment is typically prescribed for 12 weeks, but for some patients with hepatitis C virus, a longer duration may be needed.

Portal hypertension creates problems in patients coinfected with HIV and hepatitis C virus.

Patients who have both HIV and hepatitis C, and also have portal hypertension, are a very special concern.

Patients who have human immunodeficiency virus (HIV) infection are at elevated risk for HCV.

Once-daily tablet for hepatitis C virus contains sofosbuvir, velpatasvir, and voxilaprevir.

A once-daily tablet could potentially treat patients with hepatitis c virus genotypes 1 through 6.

Majority of people with chronic hepatitis C are unaware of the infection.

Trained clinical pharmacists can effectively manage patients with hepatitis C virus.

Trained clinical pharmacists can effectively manage patients with hepatitis C virus, according to research presented at the ASHP Midyear 2016 Clinical Meeting and Exhibition.

Reovirus may treat primary liver cancer and hepatitis C virus.

Different hepatitis C genotypes are more prominent in certain areas than others.

The Cherokee Nation has partnered with the CDC and other government agencies to increase awareness about hepatitis C virus.

Zepatier shows promise across genotypes 1 and 4, even among patients administered opioid agonist therapy.

Clinical trials of ARC-520 have been placed on hold by the FDA.

Individuals with hepatitis C virus genotypes 1-3 benefited from treatment with MK-3682B

Women with genetic variants had lower hepatitis C viral levels after childbirth.

Surprising findings from a study revealed that losing weight may not help protect against liver and colon cancer.

Two existing drugs, Gemcitabine and DON, target the degradation of nucleotides in the liver.

Women with genetic variants had lower hepatitis C viral levels after childbirth.

Targeting TAZ can essentially stop fibrosis and may provide future treatment options for patients with nonalcoholic steatohepatitis.

Individuals with hepatitis C virus genotypes 1 -3 benefitted from treatment with MK-3682B

Reports show that sales and revenue from Hepatitis C treatments are declining. What does this mean for patients?